Overcoming the impact of the COVID-19 pandemic on oncology early phase trials and drug development in Asia-Experiences and perspectives of the Asian Oncology Early Phase 1 Consortium아시아 종양학 초기 1 단계 컨소시엄의 종양학 초기 단계 시험 및 약물 개발에 대한 Covid-19 Pandemic의 영향을 극복Article Published on 2021-08-012022-08-31 Journal: Asia-Pacific journal of clinical oncology [Category] MERS, SARS, 신약개발, 임상, [키워드] analyzed Asia Asian benefit clinical trial coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 pandemic dependent on Determining deviation Drug development early phase enrolled Enrollment FIVE global pandemic Guidance had no Hong Kong initial Japan limit MOST Novel coronavirus novel coronavirus disease oncology outbreak outcomes pandemic Patient Patients with cancer Perspective Phase 1 phase 1. protocol public health emergency recommendation reported required risk Singapore situation South Korea Specific Sponsor Taiwan Treatment Trial trial termination [DOI] 10.1111/ajco.13510 PMC 바로가기 [Article Type] Article